2,825
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG

ORCID Icon, ORCID Icon, , , , , , , ORCID Icon, , , & show all
Pages 1304-1311 | Received 23 May 2021, Accepted 26 Jul 2021, Published online: 20 Aug 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tero Ylisaukko-oja, Minna Puttonen, Jari Jokelainen, Mirkka Koivusalo, Klaus Tamminen, Saku Torvinen & Markku Voutilainen. (2022) Dose–escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scandinavian Journal of Gastroenterology 57:4, pages 415-423.
Read now

Articles from other publishers (7)

S. Saibeni, C. Bezzio, F. Bossa, A.C. Privitera, S. Marchi, J. Roselli, S. Mazzuoli, A. Geccherle, A. Soriano, M.B. Principi, A. Viola, L. Sarpi, M. Cappello, R. D'Incà, M. Mastronardi, G. Bodini, M. Guerra, A. Benedetti, M. Romano, M. Cicala, A. Di Sabatino, F. Scaldaferri, T. De Rosa, A.M. Giardino, V. Germano, A. Orlando & A. Armuzzi. (2024) Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study. Digestive and Liver Disease 56:1, pages 83-91.
Crossref
Rirong Chen, Yizhe Tie, Yongle Huang, Xi Zhang, Zhirong Zeng, Minhu Chen, Li Li & Shenghong Zhang. (2023) Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes. United European Gastroenterology Journal.
Crossref
Andreas Blesl, Andrea Borenich, Hans Peter Gröchenig, Gottfried Novacek, Christian Primas, Walter Reinisch, Maximilian Kutschera, Constanze Illiasch, Barbara Hennlich, Pius Steiner, Robert Koch, Wolfgang Tillinger, Thomas Haas, Gerhard Reicht, Andreas Mayer, Othmar Ludwiczek, Wolfgang Miehsler, Karin Steidl, Lukas Binder, Franziska Baumann-Durchschein, Stefan Fürst, Simon Reider, Christina Watschinger, Heimo Wenzl, Alexander Moschen, Andrea Berghold & Christoph Högenauer. (2023) Factors Associated with Response to Systemic Corticosteroids in Active Ulcerative Colitis: Results from a Prospective, Multicenter Trial. Journal of Clinical Medicine 12:14, pages 4853.
Crossref
Aditi Kumar, Nuha Yassin, Alexandra Marley, Vittoria Bellato, Caterina Foppa, Gianluca Pellino, Pär Myrelid, Monica Millan, Beatriz Gros, Nicolas Avellaneda, Ignacio Catalan-Serra, Alaa El-Hussuna, João A. Cunha Neves, Joana Roseira, Miguel F. Cunha, Bram Verstockt, Dominik Bettenworth, Diane Mege & Matthew J. Brookes. (2023) Crossing barriers: the burden of inflammatory bowel disease across Western Europe. Therapeutic Advances in Gastroenterology 16.
Crossref
Daisuke Hirayama, Satoshi Motoya, Toshifumi Ashida, Katsuyoshi Ando, Mikihiro Fujiya, Takahiro Ito, Shigeru Furukawa, Atsuo Maemoto, Takehiko Katsurada, Shiro Hinotsu, Noriko Sato, Naomi Mizuno, Yoshiko Ikawa & Hiroshi Nakase. (2023) Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix Study. Inflammatory Intestinal Diseases 8:3, pages 115-127.
Crossref
Marc Ferrante, Anja Schirbel, Marieke J. Pierik, Thomas Haas, Mathurin Flamant, Ahmed Khalifa, George Philip, Freddy Cornillie, Alan G. Meehan & Marinella Govoni. (2022) Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study. European Journal of Gastroenterology & Hepatology 34:6, pages 646-654.
Crossref
Shiro Nakamura, Teita Asano, Yoshihito Tanaka, Kanami Sugimoto, Shinichi Yoshigoe & Yasuo Suzuki. (2022) Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan. Inflammatory Intestinal Diseases 7:3-4, pages 128-138.
Crossref